Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Verastem, Inc.
  6. Summary
    VSTM   US92337C1045

VERASTEM, INC.

(VSTM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
1.59(c) 1.53(c) 1.48(c) 1.54(c) 1.655 Last
2 014 485 2 963 070 2 788 051 2 419 511 2 352 186 Volume
-3.64% -3.77% -3.27% +4.05% +7.47% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1,30 M - -
Net income 2021 -72,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,76x
Yield 2021 -
Sales 2022 12,5 M - -
Net income 2022 -55,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,40x
Yield 2022 -
Capitalization 281 M 281 M -
Capi. / Sales 2021 215x
Capi. / Sales 2022 22,4x
Nbr of Employees 49
Free-Float 99,1%
More Financials
Company
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The CompanyÔÇÖs marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a... 
Sector
Biotechnology & Medical Research
Calendar
01/28 | 09:30amPresentation
More about the company
Ratings of Verastem, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about VERASTEM, INC.
01/11VERASTEM, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits..
AQ
01/11Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Adv..
BU
01/07Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
01/04Verastem Oncology to Participate in Upcoming Investor Conferences
BU
2021Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination ..
CI
2021Verastem Oncology to Present at the Jefferies London Healthcare Conference
BU
2021VERASTEM : Q3 Earnings Snapshot
AQ
2021VERASTEM, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
2021Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
2021Earnings Flash (VSTM) VERASTEM ONCOLOGY Posts Q3 Revenue $2,000
MT
2021Earnings Flash (VSTM) VERASTEM ONCOLOGY Posts Q3 Loss $-0.07
MT
2021Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Co..
BU
2021Verastem Oncology Appoints Michelle Robertson to Board of Directors - Form 8-K
PU
2021VERASTEM, INC. : Change in Directors or Principal Officers, Financial Statements and Exhib..
AQ
2021Verastem Oncology Appoints Michelle Robertson to Board of Directors
BU
More news
News in other languages on VERASTEM, INC.
2021Earnings Flash (VSTM) VERASTEM ONCOLOGY affiche un chiffre d'affaires de 2 000 $ au 3e ..
2021Les actions du secteur de la santé sombrent avec les marchés plus larges
2021Verastem déclare que l'étude de la thérapie combinée avec le VS-6766 montre un potentie..
2021Verastem annonce une perte plus importante et une baisse des recettes au deuxième trime..
2021Earnings Flash (VSTM) VERASTEM ONCOLOGY affiche un revenu de 500 000 $ au deuxième trim..
More news
Analyst Recommendations on VERASTEM, INC.
More recommendations
Chart VERASTEM, INC.
Duration : Period :
Verastem, Inc. Technical Analysis Chart | VSTM | US92337C1045 | MarketScreener
Technical analysis trends VERASTEM, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,54 $
Average target price 6,25 $
Spread / Average Target 306%
EPS Revisions
Managers and Directors
Brian M. Stuglik Chief Executive Officer & Director
Daniel W. Paterson President & Chief Operating Officer
Robert E. Gagnon Chief Financial & Business Officer
Jonathan Pachter Chief Scientific Officer
Louis J. Denis Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VERASTEM, INC.-24.88%281
GILEAD SCIENCES, INC.-5.56%86 013
REGENERON PHARMACEUTICALS-1.60%64 979
VERTEX PHARMACEUTICALS4.59%58 397
WUXI APPTEC CO., LTD.-7.49%51 604
BIONTECH SE-41.44%36 465